Activation-induced killer cell immunoglobulin-like receptor 3DL2 binding to HLA-B27 licenses pathogenic T cell differentiation in spondyloarthritis by Ridley, Anna et al.
ARTHRITIS & RHEUMATOLOGY
Vol. 68, No. 4, April 2016, pp 901–914
DOI 10.1002/art.39515
VC 2016 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc.
on behalf of the American College of Rheumatology. This is an open access article
under the terms of the Creative Commons Attribution License, which permits use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Activation-Induced Killer Cell Immunoglobulin-like Receptor
3DL2 Binding to HLA–B27 Licenses Pathogenic T Cell
Differentiation in Spondyloarthritis
Anna Ridley,1 Hiroko Hatano,1 Isabel Wong-Baeza,2 Jacqueline Shaw,1
Katherine K. Matthews,3 Hussein Al-Mossawi,1 Kristin Ladell,4 David A. Price,5
Paul Bowness,1 and Simon Kollnberger6
Objective. In the spondyloarthritides (SpA),
increased numbers of CD41 T cells express killer cell
immunoglobulin-like receptor 3DL2 (KIR-3DL2). The
aim of this study was to determine the factors that
induce KIR-3DL2 expression, and to characterize the
relationship between HLA–B27 and the phenotype and
function of KIR-3DL2–expressing CD41 T cells in SpA.
Methods. In total, 34 B271 patients with SpA, 28
age- and sex-matched healthy controls (20 B272 and
8 B271), and 9 patients with rheumatoid arthritis were
studied. KIR-3DL2 expression and other phenotypic char-
acteristics of peripheral blood and synovial fluid CD41 T
cells were studied by flow cytometry, quantitative polymer-
ase chain reaction, and Western blotting. T cell receptor
clonality was determined by template-switch anchored
reverse transcription–polymerase chain reaction and
sequencing analysis. Cytokines were measured by enzyme-
linked immunosorbent assay.
Results. Cellular activation induced KIR-3DL2
expression on both naive and effector CD41 T cells.
KIR-3DL2 binding to B271 cells promoted expression
of KIR-3DL2, the Th17-specific transcription factor ret-
inoic acid receptor–related orphan nuclear receptor gt,
and the antiapoptotic factor B cell lymphoma 2. KIR-
3DL21CD41 T cells in patients with ankylosing spon-
dylitis were oligoclonal and enriched for markers of T
cell activation and for the gut homing receptor CCR9.
In the presence of B271 antigen-presenting cells, KIR-
3DL21CD41 T cells produced less interleukin-2 (IL-2)
but more IL-17. This effect was blocked by HC10, an
antibody that inhibits the binding of KIR-3DL2 to B27
heavy chains.
Conclusion. KIR-3DL2 binding to HLA–B27
licenses Th17 cell differentiation in SpA. These findings
raise the therapeutic potential of targeting HLA–B27–
KIR-3DL2 interactions for the treatment of B271
patients with SpA.
The spondyloarthritides (SpA) encompass a
group of chronic inflammatory arthritic disorders typi-
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fied by ankylosing spondylitis (AS), a condition in which
up to 94% of affected individuals express the class I
molecule HLA–B27 (1). Genome-wide association stud-
ies in AS have confirmed the key association with HLA–
B27, and identified polymorphisms in genes associated
with interleukin-17 (IL-17)–mediated immune res-
ponses, including IL-1 receptor (IL-1R) and IL-23R
(2,3). Additional studies have shown raised levels of
serum and synovial fluid IL-17 in patients with SpA
(4,5), and raised numbers of circulating Th17 cells (6).
However, the link between HLA–B27 and production
of IL-17 by immune cells is poorly understood.
We have previously shown that HLA–B27 exists
as b2-microglobulin (b2m)–free heavy chain forms,
including heavy chain dimers (7,8). B27 free heavy chain
molecules bind more strongly than other HLA class I
proteins to the killer cell immunoglobulin-like receptor
3DL2 (KIR-3DL2), promoting increased survival of
natural killer (NK) cells and CD41 T cells (9–11). In-
creased proportions of NK cells and CD41 T cells
expressing KIR-3DL2 are present in individuals with
SpA (10,12,13). These KIR-3DL21CD41 T cells are
enriched for the expression of IL-17 and IL-23R, as well
as for other Th17 cell markers, and produce interferon-
g (IFNg). Moreover, the majority of all IL-23R1 IL-
17–producing peripheral blood CD41 T cells in patients
with SpA reside in the minority KIR-3DL21 T cell
compartment (13).
In the present study, we show that CD41 T cells
up-regulate cell surface KIR-3DL2 expression upon
activation. Subsequent binding of KIR-3DL2 to HLA–
B27 maintains the expression of KIR-3DL2 and pro-
motes T cell survival and Th17 cell differentiation. In
addition, we provide evidence that this mechanism is
proinflammatory in SpA.
PATIENTS AND METHODS
Patient and control samples. Samples of heparinized
venous blood (25 ml) were obtained from 34 B271 patients with
SpA, 33 with definite AS fulfilling the modified New York crite-
ria (14), 20 B272 and 8 B271 healthy controls, and 9 disease
controls with rheumatoid arthritis (RA). Patient and control
demographics and medications are shown in Supplementary
Table 1 (available on the Arthritis & Rheumatology web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract).
Ethics permission was obtained from the Central Office for
Research Ethics Committees (approval number 06/Q1606/139),
and all subjects gave their individual written informed consent to
participate.
Separation of CD41 T cells. Peripheral blood and
synovial fluid mononuclear cells were isolated by density-gradient
centrifugation. Total or naive (CD45RO2) CD41 T cells were
separated by negative selection on magnetic beads (Miltenyi
Biotec). CD41 T cells were activated either with anti-CD2/CD3/
CD28 beads (Miltenyi Biotec) or with 125 ng/ml phorbol myris-
tate acetate (PMA) and 1mg/ml ionomycin (Sigma).
CD41 T cell coculture with antigen-presenting cells
(APCs). LBL.721.221 and LBL.721.220 APC lines transfected
with HLA–B*27:05 and other class I molecules were used, as
has been described previously (8,15). Irradiated LBL.721
APCs (100,000 cells) were incubated with 200,000 naive or
total CD41 T cells (labeled with 5,6-carboxyfluorescein succi-
nimidyl ester [Life Technologies]), followed by incubation with
100 ng/ml staphylococcal enterotoxin B (SEB; Sigma), as pre-
viously described (13). After 5–8 days, the cells were analyzed
by flow cytometry, and supernatants were collected for
enzyme-linked immunosorbent assays (ELISAs; eBioscience)
to detect IL-2 and IL-17A. Irradiated APCs were removed
after coculture, using a Dead Cell Removal kit (Miltenyi Bio-
tec), and enriched T cells were processed for RNA extraction
and quantitative polymerase chain reaction (qPCR).
For Th17 cell differentiation experiments, naive T cells
were cultured for 8 days at a 1:5 ratio with anti-CD2/CD3/
CD28 beads or at a 1:2 ratio with transfected LBL.721.220
cells and 10 ng/ml SEB along with 20 IU/ml recombinant
human IL-2 (rhIL-2; PeproTech) and 10 ng/ml rhIL-1, IL-6,
and IL-23 (PeproTech) for 8 days. Supernatants were har-
vested for cytokine assay by ELISA, and T cells were analyzed
by fluorescence-activated cell sorting (FACS) intracellular
cytokine staining for the production of IL-2, IFNg, and IL-17.
Cells were treated with monensin (BD Biosciences) overnight
before being stained for IL-2 and IFNg, using protocols
adapted from previously described methods (13). Cells were
stimulated for 6 hours with monensin and PMA and ionomy-
cin, and then stained for IL-17. For antibody-blocking experi-
ments, cells were incubated with isotype control antibodies
(IgG1/IgG2a; BioLegend) or HC10 (anti–class I heavy chain),
HD6 (anti–B27 heavy chain), ME1 (anti–HLA–B27; binds
b2m-associated B27), or DX31 (anti–KIR-3DL2) antibodies at
10 mg/ml. Antibodies were replenished after 3 days of cell
culture.
T cell receptor (TCR) sequencing. Clonotypic analy-
sis of isolated CD41 T cell populations was performed as
described previously, with minor modifications (16). Viable
KIR-3DL21 or KIR-3DL22 CD31CD41 T cells were sorted
ex vivo into 1.5-ml microtubes (10,000 cells per tube; Sarstedt)
containing 100 ml RNAlater (Applied Biosystems) using a
FACSAria II flow cytometer (BD Biosciences). Unbiased
amplification of all expressed TRB gene products was con-
ducted using a template-switch anchored reverse transcrip-
tion–PCR with a 3 0 constant region primer (5 0-TGGCTCAA
ACAAGGAGACCT-3 0). Amplicons were subcloned, sequ-
enced, and analyzed as described previously (17). The ImMuno
GeneTics nomenclature (18) was used for all sequenced gene
products.
Flow cytometry. The following antibodies were used
for flow cytometric analyses: IgG2a and anti-DX31 (AF647 in-
house conjugates; provided by Jo Philips from DNAX
Research Institute); PerCP-conjugated anti-CD3, fluorescein
isothiocyanate (FITC)–conjugated anti-CD45RO, FITC-con-
jugated anti-CD69, FITC-conjugated anti-OX40, and phycoer-
ythrin (PE)–conjugated anti-CCR6 (BD Biosciences); PE-
conjugated anti–IL-17A and PE–Cy7–conjugated anti-CD4
(eBioscience); and FITC-conjugated anti–IL-1R, FITC-
conjugated anti-CCR9, and FITC-conjugated anti–IL-23R
(R&D Systems). Dead cells were excluded using an allophyco-
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Figure 1. Expression of killer cell immunoglobulin-like receptor 3DL2 (KIR-3DL2) is induced upon CD41 T cell activation, and KIR-3DL2
expression is correlated with T cell activation in patients with spondyloarthritis (SpA). A and B, Flow cytometry plots show staining of purified
CD41 T cells from a healthy control (HC) for the expression of KIR-3DL2 before and 6 hours after stimulation with phorbol myristate acetate
(PMA) and ionomycin (Ion) (A) or the expression of KIR-3DL2 and OX40 before and 6, 24, or 48 hours after stimulation with anti-CD2/CD3/
CD28 beads (B). Representative results from 1 of 3 independent experiments are shown. C, Flow cytometry plots show staining for the expres-
sion of OX40 on peripheral blood KIR-3DL22 or KIR-3DL21 CD41 T cells from a patient with ankylosing spondylitis (AS). IgG1 and IgG2a
antibodies were used as isotype controls in the flow cytometry analyses. D, The percentage of OX401CD41 T cells expressing KIR-3DL2 was
determined in the peripheral blood from patients with AS (n5 15), B272 healthy controls (n5 15), B271 healthy controls (n5 8), and patients
with rheumatoid arthritis (RA) (n5 9) (left) or in matched peripheral blood mononuclear cell (PBMC) and synovial fluid mononuclear cell
(SFMC) samples from 5 patients with SpA (right). Values are the mean6SD. P values were determined by analysis of variance.
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cyanin–Cy7–conjugated Live/Dead stain (Invitrogen). Intracel-
lular cytokine staining was performed using PE-conjugated
anti–IL-2 (eBioscience), using protocols adapted from previ-
ously described methods (13). At least 200,000 cells/sample
were analyzed by flow cytometry, using an LSR Fortessa (BD
Biosciences). Data were analyzed using FlowJo software (ver-
sion 8.6.6; TreeStar).
Gene expression analysis by qPCR and Western
blotting. RNA extraction was performed with an Absolutely
RNA Microprep kit (Agilent Technologies), and complemen-
tary DNA was synthesized with a SuperScript VILO kit (Invi-
trogen). Gene expression levels of Bcl2, CCR6, CD3d, IL1R,
IL23R, RORC (for retinoic acid receptor–related orphan
nuclear receptor gt [RORgt]), and TBX21 (for T-bet) were
evaluated with TaqMan Gene Expression assays (Applied Bio-
systems). Amplification reactions were performed in a 7500
Fast Real-Time PCR system (Applied Biosystems), compris-
ing 1 cycle at 958C for 20 seconds, followed by 40 cycles at
958C for 3 seconds and 608C for 30 seconds. The DDCt method
was used to determine the gene expression values relative to
those for CD3d. Sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and Western blotting were performed as
described previously (8). Western blots were probed with rab-
bit polyclonal anti–KIR-3DL2 antibodies (Pierce) or mouse
anti–b-actin monoclonal antibodies (mAb) (Sigma) and horse-
radish peroxidase–conjugated goat anti-rabbit or anti-mouse
immunoglobulins (Dako).
Statistical analysis. Statistical analysis was conducted
using GraphPad Prism software version 4. P values were calcu-
lated using Student’s t-test or one-way analysis of variance
with Bonferroni correction, as indicated.
RESULTS
Induction of KIR-3DL2 expression upon CD41 T
cell activation, and correlation between KIR-3DL2 expres-
sion and T cell activation in patients with SpA. We previ-
ously detected expansion of Th17 cells expressing KIR-
3DL2 in patients with SpA (13). In this study, we sought
to determine whether T cell activation was sufficient to
induce KIR-3DL2 expression. After stimulation of hu-
man CD41 T cells with PMA and ionomycin for 6
hours, KIR-3DL2 expression was markedly increased
(Figure 1A). KIR-3DL2 expression on CD41 T cells
was also increased after stimulation with anti-CD2/CD3/
CD28 beads (Figure 1B) and in the presence of super-
antigen (results not shown). The increase in KIR-3DL2
expression was associated with coexpression of the T
cell activation marker OX40 (Figure 1B).
We next determined whether KIR-3DL2 expres-
sion was correlated with T cell activation in patients
with SpA. In B271 patients with SpA, KIR-3DL21
CD41 T cells were highly enriched for OX40 expres-
sion, a marker of CD4+ T cells that have recently expe-
rienced antigen (Figure 1C). The proportion of
OX401CD41 T cells expressing KIR-3DL2 was signifi-
cantly greater in patients with SpA compared to either
B272 healthy control subjects or RA disease controls
(Figure 1D), but was not significantly different between
patients with SpA and B271 healthy controls. The mean
6 SEM proportions of total live CD41 T cells expressing
OX40 were 1.56 0.5%, 2.86 1.1%, 1.66 0.3%, and
2.76 0.8% in patients with SpA, B271 healthy controls,
B272 healthy controls, and patients with RA, respective-
ly. Thus, the increased proportions of KIR-3DL21
OX401CD41 T cells observed in patients with SpA and
B271 healthy controls occurred as a consequence of the
increased percentages of KIR-3DL21CD41 T cells in
these groups.
We also examined KIR-3DL2 expression on
CD41 T cells from synovial fluid. KIR-3DL21CD41 T
cells were further enriched for OX40 expression in
matched synovial fluid samples from the affected joints
of 5 patients with SpA (Figure 1D).
Up-regulation of KIR-3DL2 expression on naive
CD41 T cells following activation. We next isolated
naive CD41 T cells (.96% purity) from healthy donors
and patients with AS. Fewer than 0.5% of naive CD41
T cells from patients with AS expressed KIR-3DL2 (see
Supplementary Figure 1, http://onlinelibrary.wiley.com/
doi/10.1002/art.39515/abstract). Activation with either
PMA and ionomycin or anti-CD2/CD3/CD28 beads
induced expression of KIR-3DL2, but not KIR-3DL1,
on naive T cells (Figure 2A and results not shown). Up-
regulated expression of KIR-3DL2 was induced more
slowly with anti-CD2/CD3/CD28 beads than with PMA
and ionomycin, reaching a maximum level of expression
at 48 hours (Figure 2B). Activated naive KIR-3DL21
CD41 T cells also expressed CD69 and OX40 (Figures
2A and B). Similar results were obtained using naive
CD41 T cells from cord blood (results not shown), con-
firming that KIR-3DL2 expression could also be in-
duced on antigen-inexperienced naive T cells.
Western blot analysis showed that freshly iso-
lated naive T cells expressed low levels of KIR-3DL2
(Figure 2C). Increased KIR-3DL2 protein expression
after activation with any of the stimuli was detected by
Western blotting from as early as 6 hours, reaching a
maximum level of expression with anti-CD2/CD3/CD28
bead stimulation at 8 days.
Oligoclonal TCR repertoire of KIR-3DL21
CD41 T cells in patients with SpA. We next compared
the TCR sequences from equal numbers of KIR-
3DL21 and KIR-3DL22 CD41 T cells that had been
isolated directly ex vivo from the peripheral blood of
patients with SpA and healthy controls (.96% purity,
as determined by flow cytometry [see Supplementary
Figure 2, http://onlinelibrary.wiley.com/doi/10.1002/art.
39515/abstract]). All of the TCR sequences identified
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in CD41 T cells from patients with SpA and healthy
controls are listed in Supplementary Table 2 (http://
onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract).
KIR-3DL21CD41 T cells from B271 patients with
SpA (n5 4) displayed an oligoclonal TCR repertoire,
with evidence of skewing toward dominant clonotypes
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Figure 2. Expression of KIR-3DL2 is induced by activation of naive CD41 T cells. A, Flow cytometry plots show staining for KIR-3DL2 or
KIR-3DL1 and CD69 in purified naive CD41 T cells from a patient with AS before and 6 hours after stimulation with PMA and ionomycin. B,
Flow cytometry plots show staining for KIR-3DL2 and OX40 in naive CD41 T cells from a healthy control before and 6, 24, or 48 hours after
stimulation with anti-CD2/CD3/CD28 beads as compared to unstimulated control cells. IgG1 and IgG2a antibodies were used as isotype controls
in the flow cytometry analyses. C, Western blots show the expression of KIR-3DL2, as compared to b-actin, before or after activation of purified
naive CD41 T cells from a healthy control with anti-CD2/CD3/CD28 beads for 6 hours, 24 hours, 2 days, 5 days, 8 days, or 12 days, with PMA
and ionomycin for 6 hours, or with phytohemagglutinin (PHA) for 24 hours. Representative results from 1 of 3 independent experiments are
shown. See Figure 1 for other definitions.
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(Figure 3A). Synovial fluid KIR-3DL21CD41 T cells
from a patient with AS were also oligoclonal (Figure
3B). In contrast, KIR-3DL21CD41 T cells purified
from healthy controls exhibited more diverse TCR rep-
ertoires (Figure 3C).
Overall, the mean6 SEM numbers of unique
TCR sequences in the KIR-3DL21 and KIR-3DL22
CD41 T cell populations in patients with SpA (n5 5)
were 19.86 10.5 and 39.26 9.43, respectively (P5 0.04,
by paired t-test). In contrast, the mean6 SEM numbers
of unique TCR sequences in the KIR-3DL21 and KIR-
3DL22 CD41 T cell populations in the control group
(n5 3) were not significantly different (36.676 7.06 and
336 11.02, respectively). Identical clonotypes were
detected across the KIR-3DL21 and KIR-3DL22 T
cell compartments in 3 individuals (Figure 3D and Sup-
Figure 3. KIR-3DL21CD41 T cells from patients with AS are oligoclonal. A–C, Pie charts show the distribution of distinct T cell receptor (TCR)
sequences of the KIR-3DL21 and KIR-3DL22 CD41 T cell subsets of PBMCs from 4 patients with AS (A), SFMCs from 1 patient with AS (B),
or PBMCs from 3 B272 healthy controls (C). The numbers of sequences (Seq #) are also shown. D, TCR sequences of the KIR-3DL21 and KIR-
3DL22 T cell subsets were identical in matched PBMCs and SFMCs from 1 patient with AS (patient AS5), SFMCs from 1 patient with AS (patient
AS6), and PBMCs from a B272 healthy control (HC3). Sequences marked with an asterisk were found in matched PBMC and SFMC samples.
Identical sequences are underlined. CDR35 third complementarity-determining region; Freq5 frequency (see Figure 1 for other definitions).
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plementary Table 2, http://onlinelibrary.wiley.com/doi/
10.1002/art.39515/abstract). Given their identical nucleic
acid sequences, it is likely that these T cells are the prog-
eny of individual sister clones that dynamically regulate
KIR-3DL2 expression.
Promotion of KIR-3DL2 expression and Th17
cell differentiation by CD41 T cell activation in the
presence of HLA–B27. We next activated naive CD41 T
cells from patients with AS and healthy controls with SEB
in the presence of LBL.721.221 or LBL.721.220 B cell
Figure 4. Binding of KIR-3DL2 to B27 heavy chains promotes the survival of activated naive CD41 T cells. A, Left, Flow cytometry plots show
staining for KIR-3DL2 or IgG2a isotype control in CD45RO1 T cells from a patient with AS after 5 days of stimulation with LBL.721.220 cells
(transfected with HLA–B7 [220B7] or HLA–B27 [220B27]) and staphylococcal enterotoxin B (SEB). Right, KIR-3DL2 expression in cells under
each condition is shown as the percentage of maximum (Max). B, OX401KIR-3DL21 naive CD41 T cells from a healthy control were analyzed
by Live/Dead staining to exclude dead cells (left) and identify viable cells (right), after 5 days of stimulation with the indicated LBL.721.220 cells
and SEB. Nontransfected LBL.721.220 cells (220) were used as a transfection control. Isotype control monoclonal antibody (mAb) did not stain
(results not shown). C, CD691KIR-3DL21 T cells among naive CD41 T cells from a healthy control were analyzed by Live/Dead staining to
exclude dead cells (top) and identify viable cells (bottom), after 2 days of stimulation with LBL.721.220 B271 cells and SEB with or without the
indicated mAb. In the flow cytometry analyses, representative results from 1 of 3 independent experiments are shown. D, Bcl-2 expression was
assessed by quantitative polymerase chain reaction in healthy control naive CD41 T cells cocultured with the indicated LBL.721.221 cells and
SEB for 6 or 24 hours. Results are the mean6 SEM of 5 independent experiments. P values were determined by analysis of variance. NS5not
significant (see Figure 1 for other definitions).
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lines, each of which expresses similar surface densities of
different HLA class I molecules. Both LBL.721.220 B271
cells and LBL.721.221 B271 cells express high levels of
B27 dimers and free heavy chains (7,8). Moreover, the
KIR-3DL2 receptor expressed by NK cells or reporter
cells binds equally strongly to B27 dimers and free heavy
chains expressed by transfected LBL.721.220 and
LBL.721.221 cells (9).
Although initial induction of KIR-3DL2 on
CD41 T cells occurred independently of the expressed
HLA class I allele (results not shown), higher levels of
KIR-3DL2 expression were maintained over time in the
presence of B271 APCs (Figure 4A). Naive T cells acti-
vated with LBL.721.220 B271 cell transfectants also
expressed higher levels of KIR-3DL2 messenger RNA
(mRNA), as assayed by qPCR (see Supplementary
Figure 3, http://onlinelibrary.wiley.com/doi/10.1002/art.
39515/abstract). In all cases, activated naive KIR-3DL21
cells expressed the effector memory T cell marker
CD45RO (results not shown). Similar results were
obtained with naive CD41 T cells from healthy controls
(see Supplementary Figure 4, http://onlinelibrary.wiley.
com/doi/10.1002/art.39515/abstract) and unsorted (bulk)
CD41 T cells (results not shown). Furthermore, these
cells survived better after activation in the presence of
LBL.721.220 B271 cells, compared to stimulation with
parental or control HLA class I–transfected LBL.721.220
cells (Figure 4B).
The class I heavy chain antibody HC10 inhibited
the expression of KIR-3DL2 and concomitantly decreased
the numbers of viable naive or bulk CD41 T cells stimu-
lated with LBL.721.220 B271 cells (Figure 4C and results
not shown). The KIR-3DL2–specific antibody DX31 also
inhibited survival of activated naive CD41 T cells (Figure
4C and Supplementary Figure 4, http://onlinelibrary.wiley.
com/doi/10.1002/art.39515/abstract). In contrast, the ME1
antibody, which recognizes b2m-associated HLA–B27, did
not affect KIR-3DL2 expression and cell survival of naive
T cells activated with LBL.721.220 B271 cells (Supple-
mentary Figure 4, http://onlinelibrary.wiley.com/doi/10.
1002/art.39515/abstract). In addition, activation of naive
CD41 T cells with LBL.721.221 B271 cells significantly
up-regulated Bcl2 transcript expression at 24 hours (Fig-
ure 4D). Thus, activation with B271 APCs promotes
naive CD41 T cell survival and expression of KIR-3DL2.
Inhibition of CD4+ T cell IL-2 production by
KIR-3DL2 interactions with HLA–B27 leading to Th17
cell differentiation. We next examined the functional
effect of KIR-3DL2 binding to HLA–B27 on CD41 T
cell lineage differentiation. It has been established that
IL-2 inhibits the production of IL-17, and we previously
demonstrated that KIR-3DL2 binding to HLA–B27 on
LBL.721.220 B271 cells promotes IL-17 production
(13). Moreover, KIR ligation by HLA class I inhibits IL-
2 production (19). Thus, we reasoned that KIR-3DL2
binding to B27 dimers on transfected cells could pro-
mote an IL-17–secreting phenotype by reducing CD41
T cell production of IL-2. Consistent with this notion,
LBL.721.221 B271 cells consistently stimulated greater
production of IL-17 and lower production of IL-2 by
activated T cells than did parental LBL.721.221 cells or
control transfectants (Figure 5A).
The increased production of IL-17 observed fol-
lowing stimulation of CD41 T cells with LBL.721.221
B271 and LBL.721.220 B271 cells was inhibited by
HLA class I heavy chain (HC10) antibodies and anti–
KIR-3DL2 (DX31) antibodies (see ref. 13 and Supple-
mentary Figure 5, http://onlinelibrary.wiley.com/doi/10.
1002/art.39515/abstract). HC10 antibodies inhibited IL-
17 production and promoted IL-2 production by CD41
T cells that had been stimulated with LBL.721.220 B271
cells (Figure 5B). We consistently observed lower pro-
duction of IL-2 by CD41 T cells when the cells were
stimulated with LBL.721.220 B271 cells as compared to
when they were stimulated with LBL.721.221 B271 cells.
Compared to LBL.721.221 B271 cells, LBL.721.220
B271 cells express higher levels of B27 free heavy chains,
which are capable of binding to KIR-3DL2 (8).
To extend this observation, we studied the effect
of superantigen activation on CD41 T cell differentia-
tion. Activation of naive T cells in the presence of B271
APCs consistently increased RORC gene expression (a
key Th17-specific transcription factor) by naive CD41
T cells, as compared to that following stimulation with
parental LBL.721.220 cells or control transfectants (Fig-
ure 5C). The effect on RORC expression was apparent
from 5 days after activation (results not shown).
We further reasoned that increased expression of
RORC could promote the differentiation of Th17 cells.
Accordingly, we compared IL-17 production by naive T
cells stimulated with LBL.721.220 B271 cells and
LBL.721.220 control transfectants, or anti-CD2/CD3/
CD28 beads in the presence of the Th17 cytokines IL-23,
IL-1, and IL-6, together with low concentrations of IL-2.
Activation with LBL.721.220 B271 cells and Th17 cyto-
kines promoted greater production of IL-17 by naive T
cells compared to that with the other stimuli (Figure 5D
and Supplementary Figures 5 and 6, http://onlinelibrary.
wiley.com/doi/10.1002/art.39515/abstract). Naive T cells
activated with LBL.721.220 B271 cells produced less IL-
2 compared to that after stimulation with control
LBL.721.220 cells (Figure 5D). IL-17 production by naive
T cells activated with LBL.721.220 B271 cells and Th17
cytokines was inhibited by HC10 and DX31 antibodies
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(Supplementary Figures 5 and 6, http://onlinelibrary.
wiley.com/doi/10.1002/art.39515/abstract). FACS stain-
ing showed that naive CD4+ T cells activated with
LBL.721.220 B27+ cells also produced less IL-2 com-
pared to that produced by control LBL.721.220-stimu-
lated naive CD4+ T cells (Figure 5D).
We also studied the effect of physiologic levels of
HLA–B27 expressed by Epstein-Barr virus–transformed
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Figure 5. Interactions of KIR-3DL2 with B271 antigen-presenting cells inhibit the production of interleukin-2 (IL-2) and promote Th17 cell
differentiation. A, Secretion of IL-17A and IL-2 was assessed in CD41 T cells from healthy controls (n5 6) cocultured for 5 days with
LBL.721.221 cells (left nontransfected [221] or transfected with the indicated HLA class I molecules) and SEB. Values for T cells stimulated
with LBL.721.221 B271 cells were significantly different (P , 0.05 by analysis of variance) from those in T cells cocultured under the other con-
ditions. B, Production of IL-17A and IL-2 was assessed in CD41 T cells from healthy controls (n5 3) cocultured for up to 3 days with
LBL.721.220 B271 cells, SEB, and HC10 antibodies or IgG2a as isotype control. C, Expression of the retinoic acid receptor–related orphan
nuclear receptor gt gene RORC and the T-bet gene TBX21 was assessed in naive CD41 T cells isolated from the peripheral blood of a healthy
control after coculture with the indicated LBL.721.220 cells and SEB for 8 days. Gene expression was normalized to that of CD3. Representative
results from 4 independent experiments are shown. In A–C, values are the mean6 SD. D, Representative flow cytometry plots show the propor-
tions of viable IL-171 and IL-21 naive T cells after 5 days of stimulation with Th17 cytokines (IL-1, IL-6, and IL-23) along with anti-CD2/CD3/
CD28 beads or with the indicated LBL.721.220 cells and SEB. IgG1 was used as the isotype control. See Figure 1 for other definitions.
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Figure 6. KIR-3DL21CD41 T cells from B271 patients with AS are enriched for the expression of interleukin-1 receptor (IL-1R) and CCR9. A,
Flow cytometry plots show IL-1R expression by peripheral blood KIR-3DL22 and KIR-3DL21 CD41 T cells from a representative patient with
AS. IgG1 was used for isotype control staining. B, Left, Percentages of IL-1R1CD41 T cells expressing KIR-3DL2 were determined in the peripher-
al blood of patients with AS (n5 15), B272 healthy controls (n5 15), B271 healthy controls (n5 8), and patients with RA (n5 8). Right, Gene
expression of IL1R was assessed by quantitative polymerase chain reaction in KIR-3DL21 and KIR-3DL22 CD41 peripheral blood T cells from a
B272 healthy control and a patient with AS. Gene expression was normalized to that of CD3. Representative results from 3 independent experi-
ments are shown. C, Flow cytometry plots show CCR9 expression by peripheral blood KIR-3DL22 and KIR-3DL21 CD41 T cells from a represen-
tative patient with AS. IgG2a was used for isotype control staining. D, Percentages of CCR91CD41 T cells expressing KIR-3DL2 were determined
in the peripheral blood of B271 patients with AS (n5 15), B272 healthy controls (n5 15), B271 healthy controls (n5 8), and patients with RA
(n5 8). Values in B and D are the mean6 SEM. P values were determined by analysis of variance. See Figure 1 for other definitions.
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B cell lines on the differentiation of naive T cells activat-
ed with Th17 cytokines and superantigen. Differentia-
tion of naive T cells with B27-expressing B cell lines
promoted greater production of IL-17 than differentia-
tion with cell lines that did not express B27 (Supplemen-
tary Figure 7, http://onlinelibrary.wiley.com/doi/10.1002/
art.39515/abstract). Production of IL-17 by naive T cells
stimulated with B271 B cell lines was inhibited by both
anti–class I heavy chain and anti–KIR-3DL2 mAb (Sup-
plementary Figure 7, http://onlinelibrary.wiley.com/doi/
10.1002/art.39515/abstract).
We have previously shown that the mAb HD6,
which recognizes B27 heavy chain dimers, inhibits IL-17
production by CD41 T cells from patients with SpA
(20). Compared to the HC10 mAb, HD6 has a lower
avidity for B27 free heavy chains and recognizes a dis-
tinct epitope (Marroquin O, et al: unpublished observa-
tions). Our previous results have shown that HD6
inhibits the survival of KIR-3DL21 T cells (9). In this
study, we found that HD6 inhibited the survival of KIR-
3DL21CD41 T cells in the peripheral blood of patients
with SpA (see Supplementary Figure 8, http://onlineli-
brary.wiley.com/doi/10.1002/art.39515/abstract).
Collectively, these results show that the interaction
between KIR-3DL2 and B271 APCs can skew the differ-
entiation of CD41 T cells toward a Th17 cell phenotype.
Enrichment for gut homing and Th17 cell differ-
entiation markers of KIR-3DL21CD41 T cells from
patients with SpA. We previously found that KIR-
3DL21CD41 T cells in patients with SpA are enriched
for the expression of the Th17 cell markers IL-23R and
CCR6 (13). To extend these findings, we studied addi-
tional differentiation and homing markers by flow
cytometry and qPCR. Peripheral blood KIR-3DL21
CD41 T cells from patients with SpA were enriched for
both IL-23R and CCR6 expression, at both the protein
and transcript levels, as compared to KIR-3DL22
CD41 T cells both from patients with SpA and from
B272 healthy controls (see Supplementary Figure 9, http://
onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract).
Representative flow cytometry data from a patient with AS
revealed an enrichment of IL-1R expression on peripheral
blood KIR-3DL21CD41 T cells (Figure 6A). Significant-
ly greater expression of KIR-3DL2 on IL-1R1CD41 T
cells was detected in B271 patients with AS and B271
healthy controls compared to B272 healthy controls and
RA disease controls (Figure 6B). KIR-3DL21CD41 T
cells from patients with SpA also expressed higher levels of
IL-1R mRNA (Figure 6B). Notably, we did not observe
significant differences in cell surface expression levels of
the Th17 phenotypic markers on CD41 T cells lacking
KIR-3DL2 in any of the groups studied.
Increased expression of the gut chemokine
receptor CCR9 was also detected on peripheral KIR-
3DL21CD41 T cells from patients with AS and B271
healthy controls (Figures 6C and D). Remarkably, 40%
of all circulating CCR91CD41 T cells in patients with
SpA expressed KIR-3DL2 (Figure 6D). Moreover,
CCR9 expression on synovial fluid KIR-3DL21CD41
T cells was elevated in patients with SpA (results not
shown). Similar to our observations with Th17 pheno-
typic markers, we did not observe significant differences
in the level of CCR9 expression on CD41 T cells lack-
ing KIR-3DL2 expression in any of the groups studied.
Thus, the increased proportions of KIR-3DL21IL-1R1
and CCR91 CD41 T cells observed in patients with
SpA occurred as a consequence of the increased percen-
tages of KIR-3DL21CD41 T cells.
KIR-3DL21CD41 T cells also were found to
produce more IL-6 (Supplementary Figure 9, http://
onlinelibrary.wiley.com/doi/10.1002/art.39515/abstract),
but not IL-5 or IL-10 (results not shown), in response to
stimulation with anti-CD2/CD3/CD28 beads.
DISCUSSION
In this study, we showed that KIR-3DL2 is tran-
siently up-regulated on the surface of CD41 T cells upon
activation. Subsequent binding of KIR-3DL2 to B27 free
heavy chains on the surface of APCs maintains receptor
expression and promotes Th17 cell differentiation and
IL-17 production. These results suggest a mechanism
whereby HLA–B27 predisposes individuals to the devel-
opment of SpA. Moreover, the presence of oligoclonal
KIR-3DL21CD41 T cell populations expressing markers
of activation and Th17 cell lineage commitment in the
blood and joints of patients with SpA provides strong evi-
dence that this process occurs in vivo.
KIR expression on CD81 T cells following TCR
ligation has been reported previously (21). Similarly, the
results of this study show, for the first time, that KIR-
3DL2 is expressed by CD41 T cells in response to acti-
vation. Freshly isolated naive CD41 T cells expressed
low levels of KIR-3DL2 both transcriptionally and in
protein form. However, surface up-regulation of KIR-
3DL2 was detected within 6 hours of activation, indicat-
ing that rapid translational activity is induced upon stim-
ulation. It is notable in this regard that the presence of
KIR transcripts has been detected previously in T cells
lacking surface expression of the encoded receptor (22).
The KIR-3DL2 promoter region is unique among the
KIR family gene promoters, as it incorporates multiple
potential binding sites for NF-kB, which could play a
role in activation-induced expression (23).
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The presence of B271 APCs both maintained
KIR-3DL2 expression by CD41 T cells and skewed dif-
ferentiation toward a Th17 or Th1/Th17 phenotype. We
consider this a form of “licensing” in terms of lineage
commitment. T cells with both a Th1 and a Th17 pheno-
type have been observed in patients with Crohn’s dis-
ease (24) and in those with juvenile idiopathic arthritis
(25). How might the interaction between KIR-3DL2
and HLA–B27 drive CD41 T cells to produce IL-17?
We propose that KIR-3DL2 binding to noncanonical
B27 free heavy chains enhances RORgt (and Bcl-2)
expression, perhaps through a net decrease in CD3-
transduced signaling strength. Indeed, weak TCR sig-
nals promote Th17 responses (26). Consistent with this
possibility, we observed reduced production of IL-2 by
CD41 T cells stimulated with B271 APCs, a phenome-
non that correlated temporally with the induction of
KIR-3DL2. It is also established that IL-2 inhibits the
production of IL-17 by CD41 T cells (27). Accordingly,
inhibition of KIR-3DL2 binding to B27 free heavy
chains increased T cell production of IL-2 and de-
creased production of IL-17 by CD41 T cells. Several
observations further support this proposed mechanism.
First, the ZAP70 kinase mutation in SKG mice attenu-
ates TCR signaling and predisposes to a disease resem-
bling SpA, through increased production of IL-17 and
decreased production of IL-2 (28). Second, reduced
production of IL-2 by T cells has been observed in AS
(29,30). Third, dendritic cells from HLA–B27–transgenic
rats display impaired conjugate formation and promote
Th17 responses (31,32). These findings are consistent with
an immunoregulatory role for cell surface B27 free heavy
chains, which are expressed by transgenic rat dendritic
cells (33).
We also show that KIR-3DL21CD41 T cells
are enriched for expression of OX40 and for IL-6 pro-
duction. Both IL-6 and OX40–OX40L interactions posi-
tively regulate Th17 responses (34). Notably, IL-6 levels
are correlated with the levels of inflammation markers
in SpA (35).
The oligoclonal and highly skewed TCR reper-
toires observed in KIR-3DL21CD41 T cell populations
from patients with SpA further support the hypothesis
that KIR-3DL2 induction occurs during a process of
antigen-driven T cell activation. Intriguingly, we also
detected identical clonotypes within individuals that were
shared between the KIR-3DL21 and KIR-3DL22 CD41
T cell compartments. The presence of these nucleotide-
identical sequences strongly suggests that individual T cell
clones can dynamically modulate KIR-3DL2 expression.
Differential functionality has also been described for T cell
clones bearing different NK cell receptors in the synovial
fluid of patients with SpA, although KIR-3DL2 was not
included in that analysis (36).
KIR-3DL21CD41 T cells from synovial fluid
samples were further enriched for IL-1R and OX40
expression as compared to matched samples from the
peripheral blood. This finding suggests that activation-
induced KIR-3DL2 expression could promote the sur-
vival of CD41 T cells expressing IL-1R and IL-23R at
sites of inflammation. The expression of OX40 by
synovial KIR-3DL21CD41 T cells further supports
our hypothesis that antigen-induced activation is a
disease-relevant process in SpA. Consistent with this
interpretation, we observed oligoclonal expansions in
the synovial KIR-3DL21CD41 T cell subset in some
patients with SpA. Trafficking of KIR-3DL21CD41 T
cells between sites of inflammation and the periphery
is supported by our observation of shared clonotypes
in matched peripheral blood and synovial fluid KIR-
3DL21CD41 T cells isolated from 2 patients with
SpA. Moreover, the fact that KIR-3DL21CD41 T
cells were enriched for CCR9 expression suggests a
possible intestinal origin. It is notable in this regard
that up to 70% of patients with AS exhibit subclinical
terminal ileitis (37).
Despite the fact that up to 94% of individuals
with AS express B27 (1), the mechanistic link that
underlies this HLA-associated disease remains unex-
plained. Our data support a 2-step model, whereby T
cell activation induces KIR-3DL2 expression, and sub-
sequent interaction with B27 free heavy chains pro-
motes Th17 cell differentiation and survival. The same
process may also occur on NK cells and CD81 T cells,
both of which can express KIR-3DL2. In this scenario,
the observed HLA linkage could be explained by the
fact that KIR-3DL2 binds more strongly to B27 dimers
and free heavy chains compared to other HLA class I
heavy chains (9,38). It is likely that by priming T cells to
produce IL-17, this mechanism could act in concert with
other mechanisms that have been proposed to enhance
Th17 cytokine production in SpA, such as promotion of
the unfolded protein response by B27 (39). Collectively,
these findings suggest that targeting HLA–B27–KIR-
3DL2 interactions could be therapeutically beneficial in
patients with SpA.
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